Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: A prospective observational study

Critical Care

Volumn 15, Issue 4, 2011, Pages

  Hasslacher, Julia ^a   Bijuklic, Klaudija ^a   Bertocchi, Cristina ^a   Kountchev, Jordan ^a   Bellmann, Romuald ^a   Dunzendorfer, Stefan ^a   Joannidis, Michael ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LEVOSIMENDAN; NORADRENALIN; PHORBOL 13 ACETATE 12 MYRISTATE; REACTIVE OXYGEN METABOLITE; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE HEART FAILURE; ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; HEART HEMODYNAMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY FUNCTION; MALE; NEUTROPHIL; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SEPTIC SHOCK; ACUTE DISEASE; AUSTRIA; DRUG ANTAGONISM; DRUG EFFECT; HEART FAILURE; MIDDLE AGED; PATHOPHYSIOLOGY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; AUSTRIA; CARDIOTONIC AGENTS; FEMALE; FLOW CYTOMETRY; HEART FAILURE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; NEUTROPHILS; PROSPECTIVE STUDIES; PYRIDAZINES; REACTIVE OXYGEN SPECIES; SHOCK, SEPTIC;

EID: 79960189784     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10307     Document Type: Article

References (41)

1. Geppert A, Steiner A, Zorn G, le-Karth G, Koreny M, Haumer M, Siostrzonek P, Huber K, Heinz G. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 2002, 30:1987-1994. 10.1097/00003246-200209000-00007, 12352031.
2. Geppert A, Dorninger A, le-Karth G, Zorn G, Heinz G, Huber K. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2006, 34:2035-2042. 10.1097/01.CCM.0000228919.33620.D9, 16775569.
3. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003, 107:2998-3002. 10.1161/01.CIR.0000075927.67673.F2, 12821585.
4. Reichlin T, Socrates T, Egli P, Potocki M, Breidthardt T, Arenja N, Meissner J, Noveanu M, Reiter M, Twerenbold R, Schaub N, Buser A, Mueller C. Use of myeloperoxidase for risk stratification in acute heart failure. Clin Chem 2010, 56:944-951. 10.1373/clinchem.2009.142257, 20413430.
5. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005, 115:500-508. 1052012, 15765131.
6. Eleuteri E, Magno F, Gnemmi I, Carbone M, Colombo M, La RG, Anzalone R, Genta FT, Zummo G, Di SA, Giannuzzi P. Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Front Biosci 2009, 14:2230-2237.
7. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 2005, 3:221-229. 10.2174/1570161054368607, 2225532, 16026319.
8. Martins PS, Kallas EG, Neto MC, Dalboni MA, Blecher S, Salomao R. Upregulation of reactive oxygen species generation and phagocytosis, and increased apoptosis in human neutrophils during severe sepsis and septic shock. Shock 2003, 20:208-212. 10.1097/01.shk.0000079425.52617.db, 12923490.
9. Merx MW, Weber C. Sepsis and the heart. Circulation 2007, 116:793-802. 10.1161/CIRCULATIONAHA.106.678359, 17698745.
10. Muller-Werdan U, Buerke M, Ebelt H, Heinroth KM, Herklotz A, Loppnow H, Russ M, Schlegel F, Schlitt A, Schmidt HB, Soffker G, Werdan K. Septic cardiomyopathy - A not yet discovered cardiomyopathy?. Exp Clin Cardiol 2006, 11:226-236. 2276158, 18651035.
11. Tavernier B, Mebazaa A, Mateo P, Sys S, Ventura-Clapier R, Veksler V. Phosphorylation-dependent alteration in myofilament ca2+ sensitivity but normal mitochondrial function in septic heart. Am J Respir Crit Care Med 2001, 163:362-367.
12. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006, 104:556-569. 10.1097/00000542-200603000-00024, 16508404.
13. Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006, 98:102-106. 10.1016/j.amjcard.2006.01.068, 16784930.
14. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, Kallikazaros I. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005, 7:882-887. 10.1016/j.ejheart.2005.02.002, 15921958.
15. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, Iliodromitis E, Kremastinos D. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004, 93:1309-1312. 10.1016/j.amjcard.2004.01.073, 15135713.
16. Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, Venetsanou K, Lekakis J, Kremastinos DT. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005, 96:423-426. 10.1016/j.amjcard.2005.03.092, 16054474.
17. Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs 2008, 17:1143-1150. 10.1517/13543784.17.8.1143, 18616411.
18. Morelli A, Ertmer C, Westphal M. Calcium sensitizing in sepsis: is levosimendan on the right path?. Crit Care Med 2008, 36:1981-1982. 10.1097/CCM.0b013e318176a807, 18520666.
19. Noto A, Giacomini M, Palandi A, Stabile L, Reali-Forster C, Iapichino G. Levosimendan in septic cardiac failure. Intensive Care Med 2005, 31:164-165. 10.1007/s00134-004-2502-3, 15580334.
20. Powell BP, De Keulenaer BL. Levosimendan in septic shock: a case series. Br J Anaesth 2007, 99:447-448. 10.1093/bja/aem225, 17702832.
21. Morelli A, De CS, Teboul JL, Singer M, Rocco M, Conti G, De LL, Di AE, Orecchioni A, Pandian NG, Pietropaoli P. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005, 31:638-644. 10.1007/s00134-005-2619-z, 15812624.
22. Morelli A, Donati A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, Landoni G, Pelaia P, Pietropaoli P, Van AH, Teboul JL, Ince C, Westphal M. Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study. Crit Care 2010, 14:R232. 10.1186/cc9387, 21182783.
23. Schwarte LA, Schwartges I, Thomas K, Schober P, Picker O. The effects of levosimendan and glibenclamide on circulatory and metabolic variables in a canine model of acute hypoxia. Intensive Care Med 2011, 37:701-710. 10.1007/s00134-011-2144-1, 3058361, 21380525.
24. Stuart-Smith K. Levosimendan: from coronary care to intensive care?. Intensive Care Med 2011, 37:569-571. 10.1007/s00134-011-2204-6, 21380519.
25. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002, 42:43-51. 10.1177/0091270002042001005, 11808823.
26. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003, 29:530-538.
27. Parissis JT, Andreadou I, Markantonis SL, Bistola V, Louka A, Pyriochou A, Paraskevaidis I, Filippatos G, Iliodromitis EK, Kremastinos DT. Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis 2007, 195:e210-e215. 10.1016/j.atherosclerosis.2007.07.011, 17707851.
28. Maytin M, Colucci WS. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005, 96:26G-31G.
29. Latva-Hirvela J, Kyto V, Saraste A, Vuorinen T, Levijoki J, Saukko P. Effects of levosimendan in experimental acute coxsackievirus myocarditis. Eur J Clin Invest 2009, 39:876-882. 10.1111/j.1365-2362.2009.02202.x, 19772522.
30. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994, 343:831-836. 10.1016/S0140-6736(94)92029-X, 7908081.
31. Berger M, O'Shea J, Cross AS, Folks TM, Chused TM, Brown EJ, Frank MM. Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest 1984, 74:1566-1571. 10.1172/JCI111572, 425333, 6209300.
32. Borregaard N, Kjeldsen L, Sengelov H, Diamond MS, Springer TA, Anderson HC, Kishimoto TK, Bainton DF. Changes in subcellular localization and surface expression of L-selectin, alkaline phosphatase, and Mac-1 in human neutrophils during stimulation with inflammatory mediators. J Leukoc Biol 1994, 56:80-87.
33. Weiss M, Schneider EM, Liebert S, Mettler S, Lemoine H. Vasoactive drugs inhibit oxygen radical production of neutrophils. Immunopharmacol Immunotoxicol 1997, 19:239-263. 10.3109/08923979709007661, 9130008.
34. Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kranias EG, Solaro RJ. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995, 77:107-113.
35. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998, 98:2141-2147.
36. Ng TM. Levosimendan, a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy 2004, 24:1366-1384. 10.1592/phco.24.14.1366.43145, 15628834.
37. Pollesello P, Ovaska M, Kaivola J, Tilgmann C, Lundstrom K, Kalkkinen N, Ulmanen I, Nissinen E, Taskinen J. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994, 269:28584-28590.
38. Di VF, Lew PD, Andersson T, Pozzan T. Plasma membrane potential modulates chemotactic peptide-stimulated cytosolic free Ca2+ changes in human neutrophils. J Biol Chem 1987, 262:4574-4579.
39. Martin MA, Nauseef WM, Clark RA. Depolarization blunts the oxidative burst of human neutrophils. Parallel effects of monoclonal antibodies, depolarizing buffers, and glycolytic inhibitors. J Immunol 1988, 140:3928-3935.
40. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000, 102:2222-2227.
41. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360:196-202. 10.1016/S0140-6736(02)09455-2, 12133653.